Darzalex

The healthcare sector will be on watch Wednesday with a highly anticipated earnings report from Johnson & Johnson (NYSE:JNJ) before market open. Earnings Estimates: Analysts expect Johnson & Johnson to report fourth quarter revenue of $22.44 billion according to data from Benzinga Pro. The...

An OTC-listed large-cap biotech is seeking a main exchange listing, and it offers scope for investing in a proven biotech with two commercial partnered products on the market and more in the pipeline. The IPO Terms Copenhagen, Denmark-based GENMAB A/S/S ADR (OTC: GMXAY) has filed for offering 27.80...

Even amid the thick of earnings season, biotech stocks sway to the din produced by catalytic events, which include PDUFA action dates. Here's a rundown on the PDUFA dates scheduled for the month of May. 1. Will Second Time Be Charm For Portola? Company: Portola Pharmaceuticals Inc (...

Johnson & Johnson (NYSE: JNJ) shares are up about 20 percent since the company acquired Actelion back in January. However, despite the strong performance, Credit Suisse analyst Vamil Divan sees more upside ahead for the pharma giant. On Thursday, Credit Suisse reinstated coverage of Johnson...

Deutsche Bank has downgraded Ligand Pharmaceuticals Inc. (NASDAQ: LGND) to Sell from Hold on valuation. Despite acknowledging the long-term potential of Ligand's "more than 150 shots-on-goal," the brokerage sees downside in shares over the next one year if there is lag in revenue momentum and lack...